Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.


NDAQ:RGC - Post by User

User Avatar Image
(0)
•••
  • sungrin1309X
Post by sungrin1309on Nov 18, 2022 7:31am
136 Views
Post# 35109563

$RGC, a long lost twin of GME? - Shortsqueeze potential!!

$RGC, a long lost twin of GME? - Shortsqueeze potential!!Regencell Bioscience Limited’s (TICKER: RGC) stock is an undiscovered short squeeze potential. The short volume ratio has similar pattern as that of GameStop Corp. (TICKER: GME), whereby both averaged over 40% in the past year. In fact, RGC is more heavily shorted than GME as some days were close to 90% shorted.

However, as much as RGC and GME stock’s short volume profile is similar, not much is known about the facts and figures of RGC, which is provided below. As of 16 May 2022, RGC’s founder and CEO holds 10,539,159 ordinary shares, representing 81.0% of the total number of issued and outstanding ordinary shares in RGC. RGC’s total cumulative short volume as reported by third party data analytics provider is over 19 million shares and RGC’s total reported short volume to outstanding shares (excluding CEO and Chairman ownership ratio) is over 7 times, which is almost double that of GME. Where are all the extra shares coming from?

A short squeeze on GME created a return of 51x (current price to its historical low) to 191x (historical high to its historical low), what is the potential for RGC if there is a short squeeze?

https://www.valuewalk.com/game-stop-or-game-on-rgc-has-it-all-and-twice-more/
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities